trending Market Intelligence /marketintelligence/en/news-insights/trending/zV1ZRJMOLcI0-mcOI2u5Sw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Therapix lays off staff due to insufficient funds

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Therapix lays off staff due to insufficient funds

Therapix Biosciences Ltd. has terminated the employment of all of its staff except interim CEO Ascher Shmulewitz due to a lack of sufficient funds.

CFO Oz Adler and Chief Technologies Officer Adi Zuloff-Shani will remain in their positions until March 30, 2020, as part of their 90-day notice period.

Therapix's remaining directors and officers will continue to seek fundraising opportunities, including the Israel-based medical cannabis company's planned combination with Heavenly Rx Ltd.

In November 2019, Therapix and Destiny Bioscience Global Corp. mutually agreed to discontinue talks on a proposed merger between the two companies.